Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and durability of CHS-0214 in RA and PsO
NCT02486939Phase 3Completed
- Sponsor
- Coherus BioSciences, Inc.
- Start
- Jul 2015
- Primary completion
- Sep 2017
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of GP2015 in rheumatoid arthritis (RA) and plaque psoriasis, sponsored by Coherus BioSciences, Inc. Primary endpoints: Durability of Response (Maintenance of an ACR20 Response or Greater) at 48 weeks and Durability of Response (Maintenance of PASI-50 Response or Greater) at 48 weeks. Started Jul 2015; status: completed.
02
Drugs
GP2015
03
Conditions
rheumatoid arthritis (RA)plaque psoriasis
Beyond the preview
Go deeper on NCT02486939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02486939.